While the opioid epidemic has garnered worldwide attention, increasing methamphetamine use has drawn less scrutiny. Methamphetamine is a highly addictive psychostimulant affecting people from all backgrounds and regions. It is a potent vasoconstrictor, is associated with arrhythmias and dilated cardiomyopathy. Cardiovascular disease-related mortality is a leading cause of death in methamphetamine users. Women of childbearing age increasingly use methamphetamine and continue during pregnancy. In the short term, prenatal methamphetamine use is associated with fetal growth restriction and low birth weight in the newborn. Animal studies show reduction in uterine and umbilical blood flow following maternal methamphetamine administration. Based on currently available evidence, prenatal methamphetamine exposure has transient effects on gross motor development, no effect on language and cognition, and modest effects on behavior and executive functioning with poor inhibitory control, which may be attributable to early adversity. Further research is needed to evaluate long-term effects of prenatal methamphetamine exposure.
This is a preview of subscription content
Subscribe to Journal
Get full journal access for 1 year
only 7,71 € per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Dixon SD, Bejar R. Echoencephalographic findings in neonates associated with maternal cocaine and methamphetamine use: Incidence and clinical correlates. J Pediatrics. 1989;115:770–778. https://doi.org/10.1016/S0022-3476(89)80661-4
Dixon SD. Effects of transplacental exposure to cocaine and methamphetamine on the neonate. West J Med. 1989;150:436.
NIDA. What are the risks of methamphetamine misuse during pregnancy?. National Institute on Drug Abuse website. https://www.drugabuse.gov/publications/research-reports/methamphetamine/what-are-risks-methamphetamine-misuse-during-pregnancy. April 13, 2021 Accessed September 30, 2021.
Kevil CG, Goeders NE, Woolard MD, Bhuiyan MS, Dominic P, Kolluru GK, et al. Methamphetamine Use and Cardiovascular Disease. Arteriosclerosis, thrombosis, Vasc Biol. 2019;39:1739–46. https://doi.org/10.1161/atvbaha.119.312461
Stoneberg DM, Shukla RK, Magness MB. Global methamphetamine trends: an evolving problem. Int Crim justice Rev. 2018;28:136–61.
McKetin R, Leung J, Stockings E, Huo Y, Foulds J, Lappin JM, et al. Mental health outcomes associated with of the use of amphetamines: A systematic review and meta-analysis. EClinicalMedicine. 2019;16:81–97. https://doi.org/10.1016/j.eclinm.2019.09.014
Richards JR, Hamidi S, Grant CD, Wang CG, Tabish N, Turnipseed SD, et al. Methamphetamine use and emergency department utilization: 20 years later. J Addict. 2017;2017:4050932–4050932. https://doi.org/10.1155/2017/4050932
UNODC. World Drug Report 2020. United Nations Office on Drugs and Crime;https://wdr.unodc.org/wdr2020/field/WDR20_Booklet_2.pdf, 18- 25 (2020).
Hendricks EJ. Off-label drugs for weight management. Diabetes Metab Syndr Obes. 2017;10:223–34. https://doi.org/10.2147/DMSO.S95299
Elinore F. McCance-Katz, M, PhD. Substance Abuse and Mental Health Services Administration. The National Survery on Drug Use and Health: 2018. https://www.samhsa.gov/data/sites/default/files/cbhsq-reports/Assistant-Secretary-nsduh2018_presentation.pdf, 36-37 (2018).
Administration., SAAMHS Key substance use and mental health indicators in the United States: Results from the 2019 National Survey on Drug Use and Health (HHS Publication No. PEP20-07-01-001, NSDUH Series H-55). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Retrieved from https://www.samhsa.gov/data/. (2020).
Artigiani EE, Hsu MH, McCandlish D, and Wish ED Methamphetamine: a Regional Drug Crisis. National Drug Early Warning System 2018 https://cesar.umd.edu/sites/cesar.umd.edu/files/pubs/ndews-scs-methamphetamine-report-september-2018-final.pdf, 2–6 (2018).
Han B, Compton WM, Jones CM, Einstein EB & Volkow, ND Methamphetamine Use, Methamphetamine Use Disorder, and Associated Overdose Deaths Among US Adults. JAMA Psychiatry. https://doi.org/10.1001/jamapsychiatry.2021.2588 (2021).
Customs US, P. B. CBP enforcement statistics FY 2021. US Department of Homeland Security, Washington, DC. https://www.cbp.gov/newsroom/stats/drug-seizure-statistics (2021).
Sulzer D, Sonders MS, Poulsen NW, Galli A. Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol. 2005;75:406–33. https://doi.org/10.1016/j.pneurobio.2005.04.003
Winkelman TNA, Admon LK, Jennings L, Shippee ND, Richardson CR, Bart G. Evaluation of Amphetamine-Related Hospitalizations and Associated Clinical Outcomes and Costs in the United States. JAMA Netw Open. 2018;1:e183758–e183758. https://doi.org/10.1001/jamanetworkopen.2018.3758
Derauf C, LaGasse LL, Smith LM, Grant P, Shah R, Arria A, et al. Demographic and psychosocial characteristics of mothers using methamphetamine during pregnancy: preliminary results of the infant development, environment, and lifestyle study (IDEAL). Am J Drug Alcohol Abus. 2007;33:281–289. https://doi.org/10.1080/00952990601175029
Wright TE, Schuetter R, Tellei J, Sauvage L. Methamphetamines and pregnancy outcomes. J addiction Med. 2015;9:111–117. https://doi.org/10.1097/ADM.0000000000000101
Mattson CL, Tanz LJ, Quinn K, Kariisa M, Patel P, Davis NL. Trends and geographic patterns in drug and synthetic opioid overdose deaths - United States, 2013-2019. MMWR Morb Mortal Wkly Rep. 2021;70:202–207. https://doi.org/10.15585/mmwr.mm7006a4
Chiang M, Lombardi D, Du J, Makrum U, Sitthichai R, Harrington A, et al. Methamphetamine-associated psychosis: clinical presentation, biological basis, and treatment options. Hum Psychopharmacol. 2019;34:e2710 https://doi.org/10.1002/hup.2710
Kidd SE, Grey JA, Torrone EA, Weinstock HS. Increased methamphetamine, injection drug, and heroin use among women and heterosexual men with primary and secondary syphilis - United States, 2013–2017. MMWR Morb Mortal Wkly Rep. 2019;68:144–148. https://doi.org/10.15585/mmwr.mm6806a4
Ashok AH, Mizuno Y, Volkow ND, Howes OD. Association of stimulant use with dopaminergic alterations in users of cocaine, amphetamine, or methamphetamine: a systematic review and meta-analysis. JAMA Psychiatry. 2017;74:511–519. https://doi.org/10.1001/jamapsychiatry.2017.0135
Trivedi MH, Walker R, Ling W, dela Cruz A, Sharma G, Carmody T, et al. Bupropion and naltrexone in methamphetamine use disorder. N. Engl J Med. 2021;384:140–153. https://doi.org/10.1056/NEJMoa2020214
Perez FA, Blythe S, Wouldes T, McNamara K, Black KI, Oei JL. Prenatal methamphetamine-impact on the mother and child-a review. Addiction. 2021. https://doi.org/10.1111/add.15509
Brown JM, Hanson GR, Fleckenstein AE. Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants. J Pharmacol Exp therapeutics. 2001;296:762–767.
Khoshbouei H, Wang H, Lechleiter JD, Javitch JA, Galli A. Amphetamine-induced dopamine efflux. A voltage-sensitive and intracellular Na+-dependent mechanism. J Biol Chem. 2003;278:12070–12077. https://doi.org/10.1074/jbc.M212815200
Schmitz Y, Lee CJ, Schmauss C, Gonon F, Sulzer D. Amphetamine distorts stimulation-dependent dopamine overflow: effects on D2 autoreceptors, transporters, and synaptic vesicle stores. J Neurosci: Off J Soc Neurosci. 2001;21:5916–5924.
Saunders C, Ferrer JV, Shi L, Chen J, Merrill G, Lamb ME, et al. Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism. Proc Natl Acad Sci USA. 2000;97:6850–6855. https://doi.org/10.1073/pnas.110035297
Mantle TJ, Tipton KF, Garrett NJ. Inhibition of monoamine oxidase by amphetamine and related compounds. Biochemical Pharmacol. 1976;25:2073–2077. https://doi.org/10.1016/0006-2952(76)90432-9
Mandell AJ, Morgan M. Amphetamine induced increase in tyrosine hydroxylase activity. Nature. 1970;227:75–76. https://doi.org/10.1038/227075a0
Cruickshank CC, Dyer KR. A review of the clinical pharmacology of methamphetamine. Addiction. 2009;104:1085–1099. https://doi.org/10.1111/j.1360-0443.2009.02564.x
Barr AM, Panenka WJ, MacEwan GW, Thornton AE, Lang DJ, Honer WG, et al. The need for speed: an update on methamphetamine. addiction J psychiatry Neurosci: JPN. 2006;31:301–313.
Simon SL, Carnell J, Brethen P, Rawson R, Ling W. Cognitive impairment in individuals currently using methamphetamine. Am J Addictions. 2000;9:222–231.
Cadet JL, Brannock C. Free radicals and the pathobiology of brain dopamine systems. Neurochem Int. 1998;32:117–131. https://doi.org/10.1016/s0197-0186(97)00031-4
Shin EJ, Tran HQ, Nguyen PT, Jeong JH, Nah SY, Jang CG, et al. Role of mitochondria in methamphetamine-induced dopaminergic neurotoxicity: involvement in oxidative stress, neuroinflammation, and pro-apoptosis-a review. Neurochem Res. 2018;43:66–78. https://doi.org/10.1007/s11064-017-2318-5
Lin M, Chandramani-Shivalingappa P, Jin H, Ghosh A, Anantharam V, Ali S, et al. Methamphetamine-induced neurotoxicity linked to ubiquitin-proteasome system dysfunction and autophagy-related changes that can be modulated by protein kinase C delta in dopaminergic neuronal cells. Neuroscience. 2012;210:308–332. https://doi.org/10.1016/j.neuroscience.2012.03.004
Raineri M, Gonzalez B, Goitia B, Garcia-Rill E, Krasnova IN, Cadet JL, et al. Modafinil abrogates methamphetamine-induced neuroinflammation and apoptotic effects in the mouse striatum. PLoS One. 2012;7:e46599 https://doi.org/10.1371/journal.pone.0046599
Moratalla R, Khairnar A, Simola N, Granado N, García-Montes JR, Porceddu PF, et al. Amphetamine-related drugs neurotoxicity in humans and in experimental animals: Main mechanisms. Prog Neurobiol. 2017;155:149–170. https://doi.org/10.1016/j.pneurobio.2015.09.011
Xu E, Liu J, Liu H, Wang X, Xiong H. Role of microglia in methamphetamine-induced neurotoxicity. Int J Physiol Pathophysiol Pharm. 2017;9:84–100.
Shah A, Silverstein PS, Singh DP, Kumar A. Involvement of metabotropic glutamate receptor 5, AKT/PI3K signaling and NF-κB pathway in methamphetamine-mediated increase in IL-6 and IL-8 expression in astrocytes. J Neuroinflammation. 2012;9:52 https://doi.org/10.1186/1742-2094-9-52
Yang X, Wang Y, Li Q, Zhong Y, Chen L, Du Y, et al. The Main Molecular Mechanisms Underlying Methamphetamine- Induced Neurotoxicity and Implications for Pharmacological Treatment. Front Mol Neurosci. 2018;11:186–186. https://doi.org/10.3389/fnmol.2018.00186
Bartzokis G, Beckson M, Lu PH, Edwards N, Rapoport R, Wiseman E, et al. Age-related brain volume reductions in amphetamine and cocaine addicts and normal controls: implications for addiction research. Psychiatry Res: Neuroimaging. 2000;98:93–102.
Bartzokis G, Beckson M, Lu PH, Nuechterlein KH, Edwards N, Mintz J. Age-related changes in frontal and temporal lobe volumes in men: a magnetic resonance imaging study. Arch Gen Psychiatry. 2001;58:461–465. https://doi.org/10.1001/archpsyc.58.5.461
Thompson PM, Hayashi KM, Simon SL, Geaga JA, Hong MS, Sui Y, et al. Structural abnormalities in the brains of human subjects who use methamphetamine. J Neurosci. 2004;24:6028–6036.
McCann UD, Wong DF, Yokoi F, Villemagne V, Dannals RF, Ricaurte GA. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C] WIN-35,428. J Neurosci. 1998;18:8417–8422.
Sekine Y, Iyo M, Ouchi Y, Matsunaga T, Tsukada H, Okada H, et al. Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry. 2001;158:1206–1214.
Volkow ND, Chang L, Wang G-J, Fowler JS, Leonido-Yee M, Franceschi D, et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry. 2001;158:377–382.
Sekine Y, Minabe Y, Ouchi Y, Takei N, Iyo M, Nakamura K, et al. Association of dopamine transporter loss in the orbitofrontal and dorsolateral prefrontal cortices with methamphetamine-related psychiatric symptoms. Am J Psychiatry. 2003;160:1699–1701.
London E, Simon S, Berman S, Mandelkern M, Lichtman A, Bramen J, et al. Regional cerebral dysfunction associated with mood disturbances in abstinent methamphetamine abusers. Arch Gen Psychiatry. 2004;61:73–84.
Richards JR, Harms BN, Kelly A, Turnipseed SD. Methamphetamine use and heart failure: prevalence, risk factors, and predictors. Am J Emerg Med. 2018;36:1423–1428. https://doi.org/10.1016/j.ajem.2018.01.001
Maeno Y, Iwasa M, Inoue H, Koyama H, Matoba R. Methamphetamine induces an increase in cell size and reorganization of myofibrils in cultured adult rat cardiomyocytes. Int J Leg Med. 2000;113:201–207.
Metcalfe J, Ueland K. Maternal cardiovascular adjustments to pregnancy. Prog Cardiovasc Dis. 1974;16:363–374. https://doi.org/10.1016/0033-0620(74)90028-0
Ueland K, Novy MJ, Peterson EN, Metcalfe J. Maternal cardiovascular dynamics. IV. The influence of gestational age on the maternal cardiovascular response to posture and exercise. Am J Obstet Gynecol. 1969;104:856–864.
Burchfield DJ, Lucas VW, Abrams RM, Miller RL, DeVane CL. Disposition and pharmacodynamics of methamphetamine in pregnant sheep. Jama. 1991;265:1968–1973. https://doi.org/10.1001/jama.1991.03460150072026
Stek AM, Fisher BK, Baker RS, Lang U, Tseng C-Y, Clark KE. Maternal and fetal cardiovascular responses to methamphetamine in the pregnant sheep. Am J Obstet Gynecol. 1993;169:888–897.
Stek AM, Scott Baker R, Fisher BK, Lang U, Clark KE. Fetal responses to maternal and fetal methamphetamine administration in sheep. Am J Obstet Gynecol. 1995;173:1592–1598. https://doi.org/10.1016/0002-9378(95)90654-1
Acuff-Smith KD, Schilling MA, Fisher JE, Vorhees CV. Stage-specific effects of prenatal d-methamphetamine exposure on behavioral and eye development in rats. Neurotoxicology Teratol. 1996;18:199–215. https://doi.org/10.1016/0892-0362(95)02015-2
Bottalico B, Larsson I, Brodszki J, Hernandez-Andrade E, Casslen B, Marsal K, et al. Norepinephrine transporter (NET), serotonin transporter (SERT), vesicular monoamine transporter (VMAT2) and organic cation transporters (OCT1, 2 and EMT) in human. Placenta pre-eclamptic normotensive pregnancies Placenta. 2004;25:518–529. https://doi.org/10.1016/j.placenta.2003.10.017
Gorman MC, Orme KS, Nguyen NT, Kent EJ, Caughey AB. Outcomes in pregnancies complicated by methamphetamine use. Am J Obstet Gynecol. 2014;211:429.e421–-429.e427. https://doi.org/10.1016/j.ajog.2014.06.005
Ganapathy V. Drugs of abuse and human placenta. Life Sci. 2011;88:926–930. https://doi.org/10.1016/j.lfs.2010.09.015
Steiner E, Villén T, Hallberg M, Rane A. Amphetamine secretion in breast milk. Eur J Clin Pharm. 1984;27:123–124.
Brecht M-L, Herbeck DM. Pregnancy and fetal loss reported by methamphetamine-using women. Subst Abus. 2014;8:25–33. https://doi.org/10.4137/SART.S14125
Abdul-Khabir W, Hall T, Swanson AN, Shoptaw S. Intimate partner violence and reproductive health among methamphetamine-using women in los angeles: a qualitative pilot study. J Psychoact Drugs. 2014;46:310–316. https://doi.org/10.1080/02791072.2014.934978
Kalaitzopoulos D-R, Chatzistergiou K, Amylidi A-L, Kokkinidis DG, Goulis DG. Effect of methamphetamine hydrochloride on pregnancy outcome: a systematic review and meta-analysis. J Addiction Med. 2018;12:220–226. https://doi.org/10.1097/adm.0000000000000391
Šlamberová R, Pometlová M, Charousová P. Postnatal development of rat pups is altered by prenatal methamphetamine exposure. Prog Neuro-Psychopharmacol Biol Psychiatry. 2006;30:82–88. https://doi.org/10.1016/j.pnpbp.2005.06.006
Šlamberová R, Yamamotová A, Schutová B, Hrubá L, Pometlová M. Impact of prenatal methamphetamine exposure on the sensitivity to the same drug in adult male rats. Prague Med Rep. 2011;112:102–114.
Garcia-Bournissen F, Rokach B, Karaskov T, Koren G. Methamphetamine detection in maternal and neonatal hair: implications for fetal safety. Arch Dis Child - Fetal Neonatal Ed. 2007;92:351–355. https://doi.org/10.1136/adc.2006.100156
Won L, Bubula N, McCoy H, Heller A. Methamphetamine concentrations in fetal and maternal brain following prenatal exposure. Neurotoxicology Teratol. 2001;23:349–354.
Eriksson M, Jonsson B, Steneroth G, Zetterstrom R. Cross-sectional growth of children whose mothers abused amphetamines during pregnancy. Acta Paediatr. 1994;83:612–617. https://doi.org/10.1111/j.1651-2227.1994.tb13091.x
Smith L, Yonekura ML, Wallace T, Berman N, Kuo J, Berkowitz C. Effects of prenatal methamphetamine exposure on fetal growth and drug withdrawal symptoms in infants born at term. J Dev Behav Pediatr. 2003;24:17–23. https://doi.org/10.1097/00004703-200302000-00006
Chomchai C, Manorom N, Watanarungsan P, Yossuck P, Chomchai S. Methamphetamine abuse during pregnancy and its health impact on neonates born at Siriraj Hospital, Bangkok, Thailand. Southeast Asian J tropical Med public health. 2004;35:228–231.
Stewart JL, Meeker JE. Fetal and infant deaths associated with maternal methamphetamine abuse. J Anal Toxicol. 1997;21:515–517. https://doi.org/10.1093/jat/21.6.515
McDonnell-Dowling K, Donlon M, Kelly JP. Methamphetamine exposure during pregnancy at pharmacological doses produces neurodevelopmental and behavioural effects in rat offspring. Int J Developmental Neurosci. 2014;35:42–51. https://doi.org/10.1016/j.ijdevneu.2014.03.005
Vorhees CV, Skelton MR, Grace CE, Schaefer TL, Graham DL, Braun AA, et al. Effects of (+)-methamphetamine on path integration and spatial learning, but not locomotor activity or acoustic startle, align with the stress hyporesponsive period in rats. Int J Developmental Neurosci. 2009;27:289–298. https://doi.org/10.1016/j.ijdevneu.2008.12.003
Smith LM, LaGasse LL, Derauf C, Grant P, Shah R, Arria A, et al. Prenatal methamphetamine use and neonatal neurobehavioral outcome. Neurotoxicology Teratol. 2008;30:20–28.
Smith LM, LaGasse LL, Derauf C, Newman E, Shah R, Haning W, et al. Motor and cognitive outcomes through three years of age in children exposed to prenatal methamphetamine. Neurotoxicol Teratol. 2011;33:176–184. https://doi.org/10.1016/j.ntt.2010.10.004
Thompson VB, Heiman J, Chambers JB, Benoit SC, Buesing WR, Norman MK, et al. Long-term behavioral consequences of prenatal MDMA exposure. Physiol Behav. 2009;96:593–601.
Sussman S. Narcotic and methamphetamine use during pregnancy. Eff newborn infants Am J Dis Child. 1963;106:325–330. https://doi.org/10.1001/archpedi.1963.02080050327013
Shah R, Diaz SD, Arria A, LaGasse LL, Derauf C, Newman E, et al. Prenatal methamphetamine exposure and short-term maternal and infant medical outcomes. Am J Perinatol. 2012;29:391–400.
Smith LM, LaGasse LL, Derauf C, Grant P, Shah R, Arria A, et al. The infant development, environment, and lifestyle study: effects of prenatal methamphetamine exposure, polydrug exposure, and poverty on intrauterine growth. Pediatrics. 2006;118:1149–1156.
Nguyen D, Smith LM, LaGasse LL, Derauf C, Grant P, Shah R, et al. Intrauterine growth of infants exposed to prenatal methamphetamine: results from the infant development, environment, and lifestyle study. J pediatrics. 2010;157:337–339.
Gargari, SS, Fallahian, M, Haghighi, L, Hosseinnezhad-Yazdi, M, Dashti, E & Dolan, K. Maternal and neonatal complications of substance abuse in Iranian pregnant women. Acta Med Iran. 2012;50:411–16.
Oro AS, Dixon SD. Perinatal cocaine and methamphetamine exposure: maternal and neonatal correlates. J pediatrics. 1987;111:571–578.
Little BB, Snell LM, Gilstrap L 3rd. Methamphetamine abuse during pregnancy: outcome and fetal effects. Obstet Gynecol. 1988;72:541–544.
Nelson MM, Forfar JO. Associations between drugs administered during pregnancy and congenital abnormalities of the fetus. Br Med J. 1971;1:523–527.
Nora J, Vargo T, Nora A, Love K, Mcnamara D. Dexamphetamine: a possible environmental trigger in cardiovascular malformations. Lancet (Lond, Engl). 1970;1:1290–1291.
Heinonen OP, Slone D & Shapiro S Birth defects and drugs in pregnancy. (Publishing Sciences Group Inc., Littleton, Massachusetts, USA, 1977).
Sankaran DL, Satyan. Cardiovascular effects of prenatal methamphetamine exposure. https://clinicaltrials.gov/ct2/show/NCT04616625 (2020).
Dixon SD, Bejar R. Echoencephalographic findings in neonates assciiated with maternal cocaine and methamphetamine use: Incidence and clinical correlates. J Pediatrics. 1989;115:770–778. https://doi.org/10.1016/S0022-3476(89)80661-4
Maranella E, Mareri A, Nardi V, Di Natale C, Di Luca L, Conte E, et al. Severe neurologic and hepatic toxicity in a newborn prenatally exposed to methamphetamine. A case report. Brain Dev. 2019;41:191–194. https://doi.org/10.1016/j.braindev.2018.08.010
Chang L, Cloak C, Jiang CS, Farnham S, Tokeshi B, Buchthal S, et al. Altered neurometabolites and motor integration in children exposed to methamphetamine in utero. Neuroimage. 2009;48:391–397. https://doi.org/10.1016/j.neuroimage.2009.06.062
Eze N, Smith LM, LaGasse LL, Derauf C, Newman E, Arria A, et al. School-aged outcomes following prenatal methamphetamine exposure: 7.5-year follow-up from the infant development, environment, and lifestyle study. J pediatrics. 2016;170:34–38.e31. https://doi.org/10.1016/j.jpeds.2015.11.070
Smith LM, Diaz S, LaGasse LL, Wouldes T, Derauf C, Newman E, et al. Developmental and behavioral consequences of prenatal methamphetamine exposure: a review of the Infant Development, Environment, and Lifestyle (IDEAL) study. Neurotoxicol Teratol. 2015;51:35–44. https://doi.org/10.1016/j.ntt.2015.07.006
Morie KP, Crowley MJ, Mayes LC, Potenza MN. Prenatal drug exposure from infancy through emerging adulthood: results from neuroimaging. Drug alcohol Depend. 2019;198:39–53. https://doi.org/10.1016/j.drugalcdep.2019.01.032
Warton FL, Taylor PA, Warton CMR, Molteno CD, Wintermark P, Lindinger NM, et al. Prenatal methamphetamine exposure is associated with corticostriatal white matter changes in neonates. Metab brain Dis. 2018;33:507–522. https://doi.org/10.1007/s11011-017-0135-9
Hansen RL, Struthers JM, Gospe SM Jr. Visual evoked potentials and visual processing in stimulant drug‐exposed infants. Developmental Med Child Neurol. 1993;35:798–805.
LaGasse LL, Derauf C, Smith LM, Newman E, Shah R, Neal C, et al. Prenatal methamphetamine exposure and childhood behavior problems at 3 and 5 years of age. Pediatrics. 2012;129:681–688. https://doi.org/10.1542/peds.2011-2209
Derauf C, LaGasse LL, Smith LM, Newman E, Shah R, Neal CR, et al. Prenatal methamphetamine exposure and inhibitory control among young school-age children. J pediatrics. 2012;161:452–459.
Wouldes TA, LaGasse LL, Huestis MA, DellaGrotta S, Dansereau LM, Lester BM. Prenatal methamphetamine exposure and neurodevelopmental outcomes in children from 1 to 3 years. Neurotoxicology Teratol. 2014;42:77–84.
Kwiatkowski MA, Donald KA, Stein DJ, Ipser J, Thomas KG, Roos A. Cognitive outcomes in prenatal methamphetamine exposed children aged six to seven years. Compr psychiatry. 2018;80:24–33.
Kiblawi ZN, Smith LM, LaGasse LL, Derauf C, Newman E, Shah R, et al. The effect of prenatal methamphetamine exposure on attention as assessed by continuous performance tests: results from the Infant Development, Environment, and Lifestyle study. J Dev Behav Pediatr. 2013;34:31–37. https://doi.org/10.1097/DBP.0b013e318277a1c5
Abar B, LaGasse LL, Derauf C, Newman E, Shah R, Smith LM, et al. Examining the relationships between prenatal methamphetamine exposure, early adversity, and child neurobehavioral disinhibition. Psychol Addict Behav. 2013;27:662–673. https://doi.org/10.1037/a0030157
Huang X, Chen YY, Shen Y, Cao X, Li A, Liu Q, et al. Methamphetamine abuse impairs motor cortical plasticity and function. Mol psychiatry. 2017;22:1274–1281. https://doi.org/10.1038/mp.2017.143
Limanaqi F, Gambardella S, Biagioni F, Busceti CL, Fornai F. Epigenetic Effects Induced by Methamphetamine and Methamphetamine-Dependent Oxidative Stress. Oxid Med Cell Longev. 2018;2018:4982453 https://doi.org/10.1155/2018/4982453
Chang L, Smith LM, LoPresti C, Yonekura ML, Kuo J, Walot I, et al. Smaller subcortical volumes and cognitive deficits in children with prenatal methamphetamine exposure. Psychiatry Res. 2004;132:95–106. https://doi.org/10.1016/j.pscychresns.2004.06.004
ACOG. Methamphetamine Abuse in Women of Reproductive Age. ACOG Committee Opinion No. 479. https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Health-Care-for-Underserved-Women/Methamphetamine-Abuse-in-Women-of-Reproductive-Age?IsMobileSet=false, 1-5 (2011, reaffirmed 2021).
Wade M, Fox NA, Zeanah CH, Nelson CA. Effect of foster care intervention on trajectories of general and specific psychopathology among children with histories of institutional rearing: a randomized clinical trialeffect of foster care intervention on psychopathology among children with histories of institutional rearingeffect of foster care intervention on psychopathology among children with histories of institutional rearing. JAMA Psychiatry. 2018;75:1137–1145. https://doi.org/10.1001/jamapsychiatry.2018.2556
Windsor J, Benigno JP, Wing CA, Carroll PJ, Koga SF, Nelson CA 3rd, et al. Effect of foster care on young children’s language learning. Child Dev. 2011;82:1040–1046. https://doi.org/10.1111/j.1467-8624.2011.01604.x
Twomey J, LaGasse L, Derauf C, Newman E, Shah R, Smith L, et al. Prenatal methamphetamine exposure, home environment, and primary caregiver risk factors predict child behavioral problems at 5 years. Am J Orthopsychiatry. 2013;83:64.
Messina N, Jeter K. Parental methamphetamine use and manufacture: child and familial outcomes. J public child Welf. 2012;6:296–312.
Chu EK, Smith LM, Derauf C, Newman E, Neal CR, Arria AM, et al. Behavior problems during early childhood in children with prenatal methamphetamine exposure. Pediatrics. 2020;146:e20190270. https://doi.org/10.1542/peds.2019-0270
The authors would like to thank the funding sources listed below.
DS’s effort was supported by the Children’s Miracle Network research grant at University of California Davis, Child Health Research Grant from UC Davis Pediatrics and First Tech Federal Credit Union and Neonatal Resuscitation Program Research Grant from Canadian Pediatric Society. SL and VM received no external funding. The funder/sponsor did not participate in this work.
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Sankaran, D., Lakshminrusimha, S. & Manja, V. Methamphetamine: burden, mechanism and impact on pregnancy, the fetus, and newborn. J Perinatol 42, 293–299 (2022). https://doi.org/10.1038/s41372-021-01271-8